Worth a listen: My colleague @imjackobrien gets the 4 major health highlights from #CES2025 according to pharma/journo vet @alisonwoo: https://t.co/eJe0vXwno6
Article by my colleague @Lecia_Bushak on why @DaiichiSankyoUS launched a DTC ad for its cancer drug during #NFL's Thurs. Night Football: https://t.co/y0BLS8MrLd
Great piece by my colleague @Lecia_Bushak on RFK Jr.'s spasmodic dysphonia. I first learned about SD while writing for a speech-pathology mag in the '90s. Amazed #botox is still the go-to treatment option...https://t.co/IAPOj5Y9a2
Great op/ed by my colleague @AlisonWeissbrot: AI requires a rethink of the agency biz model. Should digital assistants be paid like FTEs? Health marketing agencies starting to grapple with this, too. https://t.co/m1JPrH0eok via @campaignliveus
I wrote about Parkinson's. Does that negate the importance of Alzheimer's? No. But when it comes to social issues, communicators risk being called out unless they speak to all points of view. @Gil_Bashe explains “whataboutism” + why it may kill empathy https://t.co/iUit5HkPRY
It's Neal Awards season + @MMMnews grabbed a nom for best single issue. What a nod to the way this team goes about meeting its far-reaching editorial remit. (Oh, and I'll be chasing another one of these myself.) Thank you, @SIIA https://t.co/ORp5w7YS0Z
My colleague @LeciaBushak interviews @CDCgov director @DrMandyCohen on how the agency plans to improve public health messaging in a post-COVID world for @MMMnews https://t.co/mnQMgjjsJN
Major dev. in copay accumulator case, as #DOJ withdraws appeal of '23 decision that vacated #HHS rule allowing insurers not to count mfr. copay assistance toward beneficiary's deductible/OOP max. Plaintiffs claim this effectively ends accumulators. https://t.co/OCixSozind
Arrived today for #JPM24. Looking forward to the delight of seeing + speaking with colleagues, and for the exhilaration of being ‘on the ground’ during one of the year’s most newsworthy weeks.
While 5% was once a dream, medicines now help people shed 20% or more body mass. Drug co's say quality, not magnitude, is their next frontier: https://t.co/Jr1srBDvU3 @mmmne
For those thinking of watching #Netflix's Pain Hustlers flick, @imjackobrien will have a review on this wk's @MMMnews podcast. For context, back in 2019, the Insys Therapeutics case was a 'punitive turning point' for #pharmamarketing https://t.co/6PGHLJelbH